Articles
Atezolizumab versus chemotherapy in patients with
platinum-treated locally advanced or metastatic urothelial
carcinoma (IMvigor211): a multicentre, open-label, phase 3
randomised controlled trial
Thomas Powles, Ignacio Durán, Michiel S van der Heijden, Yohann Loriot, Nicholas J Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta M Retz,
Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwenaëlle Gravis, Syed Hussain, Toshimi Takano, Ning Leng, Edward E Kadel III,
Romain Banchereau, Priti S Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina L Derleth, Marjorie C Green, Alain Ravaud
Summary
Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression Published Online
with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed December 18, 2017
http://dx.doi.org/10.1016/
death-ligand 1 [PD-L1]) versus chemotherapy in this patient population.
S0140-6736(17)33297-X
See Online/Comment
Methods We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic
http://dx.doi.org/10.1016/
medical centres and community oncology practices mainly in Europe, North America, and the Asia-Pacific region. S0140-6736(17)33298-1
Patients (aged ≥18 years) with metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy Barts Cancer Institute,
were randomly assigned (1:1), via an interactive voice and web response system with a permuted block design (block Experimental Cancer Medicine
size of four), to receive atezolizumab 1200 mg or chemotherapy (physician’s choice: vinflunine 320 mg/m², paclitaxel Centre, Queen Mary University
of London, St Bartholomew’s
175 mg/m², or 75 mg/m² docetaxel) intravenously every 3 weeks. Randomisation was stratified by PD-L1 expression
Hospital, London, UK
(expression on <1% [IC0] or 1% to <5% [IC1] of tumour-infiltrating immune cells vs ≥5% of tumour-infiltrating (Prof T Powles MD); Institute of
immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of Biomedicine of Seville (IBiS),
prognostic factors (none vs one, two, or three). Patients and investigators were aware of group allocation. Patients, Hospital Universitario Virgen
del Rocío/CSIC/Universidad de
investigators, and the sponsor were masked to PD-L1 expression status. The primary endpoint of overall survival was
Sevilla, Seville, Spain
tested hierarchically in prespecified populations: IC2/3, followed by IC1/2/3, followed by the intention-to-treat (I Durán MD); Institute of
population. This study, which is ongoing but not recruiting participants, is registered with ClinicalTrials.gov, number Biomedicine of Seville, Seville,
NCT02302807. Spain (I Durán); Department of
Medical Oncology, Netherlands
Cancer Institute, Amsterdam,
Findings Between Jan 13, 2015, and Feb 15, 2016, we randomly assigned 931 patients from 198 sites to receive Netherlands
atezolizumab (n=467) or chemotherapy (n=464). In the IC2/3 population (n=234), overall survival did not differ (M S van der Heijden MD);
significantly between patients in the atezolizumab group and those in the chemotherapy group (median 11·1 months Département de Médecine
Oncologique, Université
[95% CI 8·6–15·5; n=116] vs 10·6 months [8·4–12·2; n=118]; stratified hazard ratio [HR] 0·87, 95% CI 0·63–1·21;
Paris-Saclay, Gustave Roussy,
p=0·41), thus precluding further formal statistical analysis. Confirmed objective response rates were similar between Villejuif, France (Y Loriot MD);
treatment groups in the IC2/3 population: 26 (23%) of 113 evaluable patients had an objective response in the US Oncology Research,
Comprehensive Cancer Centers
atezolizumab group compared with 25 (22%) of 116 patients in the chemotherapy group. Duration of response was
of Nevada, Las Vegas, NV, USA
numerically longer in the atezolizumab group than in the chemotherapy group (median 15·9 months [95% CI 10·4 to
(N J Vogelzang MD); Istituto
not estimable] vs 8·3 months [5·6–13·2]; HR 0·57, 95% CI 0·26–1·26). In the intention-to-treat population, patients Scientifico Romagnolo per lo
receiving atezolizumab had fewer grade 3–4 treatment-related adverse events than did those receiving chemotherapy studio e la Cura dei Tumori IRST
IRCCS, Meldola, Italy
(91 [20%] of 459 vs 189 [43%] of 443 patients), and fewer adverse events leading to treatment discontinuation (34 [7%]
(U De Giorgi MD); Oncology
vs 78 [18%] patients).
Department, European Georges
Pompidou Hospital,
Interpretation Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients René Descartes University,
Paris, France
with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3). However, the safety profile for
(Prof S Oudard MD);
atezolizumab was favourable compared with chemotherapy, Exploratory analysis of the intention-to-treat population Department of Urology,
showed well-tolerated, durable responses in line with previous phase 2 data for atezolizumab in this setting. Klinikum rechts der Isar,
Technical University Munich,
Munich, Germany
Funding F Hoffmann-La Roche, Genentech.
(Prof M M Retz MD); University
Hospital 12 de Octubre,
Introduction metastatic urothelial carcinoma following platinum- Medical Oncology Department
Advanced urothelial carcinoma has a poor prognosis, containing chemotherapy vary globally. Vinflunine CIBER-ONC, Madrid, Spain
(D Castellano MD); National and
with few patients surviving more than 5 years after (approved only in the European Union [EU]) and taxanes
Kapodistrian University of
diagnosis.1 First-line cisplatin-based chemotherapy can are commonly used,4,5 with prospective clinical data for Athens Alexandra Hospital,
improve overall survival,2,3 but most patients have disease these drugs showing a modest median overall survival of Athens, Greece
progression. Treatment patterns for locally advanced or 6–7 months in this setting.6,7 In the past few years, (Prof A Bamias PhD); Centre
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 1
Articles
Léon Bérard, Lyon, France
(A Fléchon MD); Department of Research in context
Cancer Medicine, Institut Paoli
Evidence before this study overall survival in the predefined population of patients with
Calmette, Marseille, France
(G Gravis MD); Plymouth Between Jan 1, 2005, and Sep 5, 2014, we searched PubMed PD-L1 expression on 5% or more of tumour-infiltrating immune
University, Peninsula Schools and international congress presentations pertaining to phase cells, which precluded further statistical analysis. The PD-L1
of Medicine and Dentistry, 3 studies of platinum-treated urothelial carcinoma. We biomarker enriched for responses in both the chemotherapy and
Plymouth University Hospitals
searched PubMed for articles published in English with medical the atezolizumab groups, which was unexpected and partly
NHS Trust, Plymouth, UK
(Prof S Hussain MD); subject heading search terms ”advanced” AND “bladder cancer”, accounted for the negative result of the trial. Atezolizumab was
Department of Medical “urothelial carcinoma”, “transitional cell carcinoma”. Before the associated with well tolerated, durable remissions in both the
Oncology, Toranomon
present study (IMvigor211), vinflunine was the only drug PD-L1-selected and intention-to-treat populations—a finding
Hospital, Tokyo, Japan
approved by a health authority (in Europe) for the treatment of that was consistent with previous phase 2 data and that is
(T Takano MD); Genentech,
South San Francisco, CA, USA advanced or metastatic urothelial carcinoma after progression uncommon with chemotherapy. Exploratory analysis showed
(N Leng PhD, E E Kadel III BS, with platinum-based chemotherapy based on phase 3 data. differential overall survival benefit within the control group,
R Banchereau PhD,
Vinflunine and taxanes were commonly used drugs globally, based on chemotherapy choice, which could have accounted for
P S Hegde PhD,
S Mariathasan PhD, N Cui PhD, but no standard appeared to predominate, and these drugs some of the findings. Our results additionally show promise for
X Shen PhD, C L Derleth MD, were associated with poor overall survival and toxicity. Because alternative biomarkers beyond PD-L1 expression, such as
M C Green MD); and cancer immunotherapies had provided breakthroughs in tumour mutation burden. The data suggest that the risk–benefit
Department of Medical
numerous tumour types, and because urothelial carcinomas profile for atezolizumab could be acceptable in patients with
Oncology, Bordeaux University
Hospital, Bordeaux, France might be especially immunogenic on the basis of high somatic platinum-treated advanced urothelial carcinoma.
(A Ravaud MD) mutation burden, checkpoint inhibitor drugs targeting the
Implications of all the available evidence
Correspondence to: programmed death-ligand 1 (PD-L1)–anti-programmed
Five immune checkpoint inhibitors have been approved in at
Dr Thomas Powles, Barts Cancer death-1 pathway warranted investigation in this setting.
Institute, Experimental Cancer least one country for patients with platinum-treated metastatic
Single-arm phase 1 and 2 data with atezolizumab from
Medicine Centre, Queen Mary urothelial carcinoma. Data from randomised phase 3 trials exist
2014–17 have demonstrated safety and activity in this setting
University of London, for only atezolizumab and pembrolizumab. These checkpoint
St Bartholomew’s Hospital, of previously treated metastatic urothelial carcinoma.
inhibitors appear attractive compared with chemotherapy in
London E1 4NS, UK
thomas.powles@bartshealth. Added value of this study unselected patients in this setting and have potential to change
nhs.uk To our knowledge, IMvigor211 is the first phase 3 randomised the standard of care.
trial to report results for an anti-PD-L1 antibody in patients with
metastatic urothelial carcinoma. Atezolizumab did not prolong
checkpoint inhibitors have changed the treatment of results of the primary and exploratory analyses.
metastatic urothelial carcinoma.8 In a randomised phase
3 trial,9 patients with metastatic urothelial carcinoma Methods
given pembrolizumab, an anti-programmed death-1 Study design and patients
(PD-1) drug, had longer survival than did those given We conducted this multicentre, open-label, phase 3
chemotherapy. Additionally, atezolizumab—a mono- randomised controlled trial at 217 academic medical
clonal antibody that inhibits programmed death-ligand 1 centres and community oncology practices mainly in
(PD-L1) while leaving the PD-L2–PD-1 interaction Europe, North America, and the Asia-Pacific region
intact10,11—is active and well tolerated across multiple (appendix pp 9–12). The study protocol (appendix
See Online for appendix cancers, including metastatic urothelial carcinoma.11–16 pp 26–185) was approved by the independent ethics
US approval of atezolizumab in patients with committee of each study site.
platinum-treated metastatic urothelial carcinoma was Eligible patients were aged 18 years or older with
based on findings from phase 1 and 2 studies showing metastatic urothelial carcinoma, had measurable disease
durable responses with long-term clinical benefit.12,16 at baseline as per Response Evaluation Criteria In
Although atezolizumab has shown activity in patients Solid Tumors version 1·1 (RECIST v1.1), an Eastern
with all levels of PD-L1 expression, response rates were Cooperative Oncology Group (ECOG) performance
notably higher in patients with higher PD-L1 expression status of 0 or 1, and an evaluable sample for PD-L1 testing
on tumour-infiltrating immune cells.12,16 We therefore (regardless of PD-L1 status). Patients had received
designed the IMvigor211 study to compare overall no more than two previous lines of therapy and
survival with atezo lizumab to that with chemotherapy by had progressed during or following one or more
PD-L1 expression in patients with platinum-treated platinum-containing regimens for metastatic urothelial
metastatic urothelial carcinoma. To increase our carcinoma (or neoadjuvant or adjuvant therapy with
understanding of the biology of metastatic urothelial progression within 12 months). A predominance of
carcinoma, we also explored the relevance of tumour transitional histology was required. We excluded patients
mutation burden to overall survival. Here, we report with previous autoimmune disease or those who
2 www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X
Articles
1360 patients assessed for eligibility
428 ineligible
931 enrolled and randomly assigned*
467 assigned to receive 464 assigned to receive
atezolizumab chemotherapy (ITT
(ITT population) population)
8 did not receive treatment 21 did not receive treatment
459 received atezolizumab 443 received chemotherapy
(safety population) (safety population)
242 received vinflunine
148 received paclitaxel
53 received docetaxel
394 discontinued treatment 434 discontinued treatment
340 had progressive 294 had progressive
disease disease
37 had adverse events 80 had adverse events
13 patient withdrawals 38 patient withdrawals
3 at physician’s decision 21 at physician’s decision
1 was non-compliant 1 was non-compliant
65 remain on treatment 68 ongoing survival follow-up† 9 remain on treatment 80 ongoing survival follow-up†
133 remain on study 89 remain on study
334 discontinued study‡ 375 discontinued study‡
322 died 345 died
9 patient withdrawals 27 patient withdrawals
3 lost to follow-up 3 lost to follow-up
Figure 1: Trial profile
ITT=intention-to-treat. *One patient was assigned to chemotherapy twice (first to docetaxel, then to vinflunine) due to a randomisation error. This patient was
counted only once in this report. †An additional two deaths (n=1 per group) were collected from public records and were not recorded under study discontinuation, but
were included as uncensored deaths in the efficacy analyses. ‡As of data cutoff (March 13, 2017). An additional five deaths (n=4 in the chemotherapy group, n=1 in the
atezolizumab group) were collected from public records and are recorded under “patient withdrawals” and included as uncensored deaths in the efficacy analyses.
had received therapies targeting CD137, CTLA4, or ≥5% of tumour-infiltrating immune cells [IC2/3]),
PD-L1–PD-1, and patients with symptomatic brain chemotherapy type (vinflunine vs taxanes), liver
metastasis or inadequate renal or liver function. The metastases (yes vs no), and number of prognostic
appendix (pp 3–8) provides a full list of inclusion and factors (none vs one, two, or three—defined as
exclusion criteria. This study was done in accordance time from previous chemotherapy <3 months, ECOG
with Good Clinical Practice guidelines and the performance status ≥1, and haemo globin <10 g/dL).
Declaration of Helsinki. All patients provided written Investigators and participants were aware of treatment
informed consent. allocation. The primary endpoint of overall survival
mitigates most potential biases associated with an
Randomisation and masking open-label study. Patients, investigators, and the
Patients were randomly assigned (1:1), via an interactive sponsor were masked to PD-L1 expression status.
voice and web response system (IXRS) with a permuted Before randomisation, investigators selected a chemo-
block design (block size of four) to receive atezolizumab therapy regimen (vinflunine, paclitaxel, or docetaxel)
or chemotherapy. Randomisation was stratified by that the patient had not previously received. The
PD-L1 expression (expression on <1% [IC0] or 1% to sponsor was not permitted to do any population-
<5% [IC1] of tumour-infiltrating immune cells vs level summaries of outcome data until the time of
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 3
Articles
gression if deemed of clinical benefit by the investigator.
IC2/3 population ITT population
No prespecified crossover was planned per protocol.
Atezolizumab Chemotherapy Atezolizumab Chemotherapy Survival follow-up occurred every 3 months after
group (n=116) group (n=118) group (n=467) group (n=464)
treatment discontinuation. National Cancer Institute
Median age (years) 67 (43–88) 67 (36–84) 67 (33–88) 67 (31–84) Common Terminology Criteria for Adverse Events
Sex version 4.0 was used to assess adverse event frequency
Female 35 (30%) 23 (19%) 110 (24%) 103 (22%) and severity.
Male 81 (70%) 95 (81%) 357 (76%) 361 (78%) For analysis of tumour mutation burden, tumour
Race DNA extraction and preparation were done with
White 86 (74%) 88 (75%) 335 (72%) 336 (72%) HistoGeneX NV (Antwerp, Belgium). Foundation
Black or African American 0 1 (1%) 1 (<1%) 2 (<1%) Medicine (Cambridge, MA, USA) did sequencing library
Asian 16 (14%) 12 (10%) 63 (13%) 55 (12%) con struction, hybridisation capture, DNA sequencing,
Multiracial 0 1 (1%) 0 1 (<1%) and genomic alteration detection.17 In addition to
Unknown 14 (12%) 16 (14%) 68 (15%) 70 (15%) sample processing, Foundation Medicine estimated
Tobacco use the mutation burden for each sample using an algo-
Current 12/115 (10%) 18/118 (15%) 60/466 (13%) 60/462 (13%) rithm that leverages genomic alterations detected by the
Former 68/115 (59%) 68/118 (58%) 266/466 (57%) 280/462 (61%) targeted FoundationOne test to extrapolate to the whole
Never 35/115 (30%) 32/118 (27%) 140/466 (30%) 122/462 (26%) exome or genome.18 We categorised tumour mutation
Primary tumour site burden as high (at or above the median) or low (less than
Bladder 85 (73%) 88 (75%) 324 (69%) 338 (73%) the median).
Urethra 2 (2%) 5 (4%) 9 (2%) 9 (2%)
Outcomes
Renal pelvis 13 (11%) 12 (10%) 66 (14%) 52 (11%)
The primary endpoint was overall survival, defined as the
Ureter 15 (13%) 11 (9%) 60 (13%) 58 (13%)
time from randomisation to death. Secondary efficacy
Other 1 (1%) 2 (2%) 8 (2%) 7 (2%)
endpoints were investigator-assessed RECIST v1.1
Metastatic disease 99 (85%) 111 (94%) 425 (91%) 430 (93%)
objective response rate, progression-free survival, and
Site of metastases
duration of response. Confirmed objective response rates
Lymph node only 18 (16%) 27 (23%) 54 (12%) 66 (14%)
were exploratory. We additionally assessed safety and
Visceral* 78 (67%) 82 (69%) 361 (77%) 355 (77%)
prespecified patient-reported out comes (European
Liver 28 (24%) 30 (25%) 138 (30%) 130 (28%)
Organization for Research and Treatment of Cancer
ECOG performance status
Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30]
0 61 (53%) 57 (48%) 218 (47%) 207 (45%)
health-related quality of life, physical functioning, and
1 55 (47%) 61 (52%) 249 (53%) 257 (55%)
fatigue; appendix p 8).
Haemoglobin concentration 17 (15%) 19 (16%) 65 (14%) 73 (16%)
<10 g/dL
Statistical analysis
Number of risk factors†
This study was designed to enrol 931 patients, including at
0 44 (38%) 41 (35%) 145 (31%) 140 (30%)
least 230 patients with IC2/3 status and at least 537 with
1 50 (43%) 48 (41%) 214 (46%) 208 (45%)
IC1/2/3 status. Comparisons of overall survival between
2 16 (14%) 25 (21%) 86 (18%) 96 (21%)
treatment groups were tested with a hierarchical
3 6 (5%) 4 (3%) 22 (5%) 20 (4%)
fixed-sequence procedure based on a stratified log-rank
(Table 1 continues on next page)
test at a two-sided level of 5% significance (similar to that
used for objective response rate)15,16 in prespecified
primary analysis. populations: IC2/3, followed by IC1/2/3, followed by the
intention-to-treat population. The intention-to-treat
Procedures population included all randomly assigned patients
Archival or fresh tumour samples were centrally and regardless of whether they received study treatment. The
prospectively evaluated with the VENTANA SP142 PD-L1 IC2/3 and IC1/2/3 populations included all patients in
immunohistochemistry assay (Ventana Medical Systems, the intention-to-treat population with IC2/3 and IC1/2/3
Tucson, AZ, USA). Scoring criteria designated tumour status, respectively. Statistical significance was required at
samples as IC2/3, IC1, or IC0. Patients received each step before formal testing of the subsequent
atezolizumab 1200 mg or chemotherapy (vinflunine population. If overall survival benefit with atezolizumab
320 mg/m², paclitaxel 175 mg/m², or docetaxel 75 mg/m²) was statistically significant in all three populations, the
intravenously every 3 weeks until unacceptable toxicity, null hypothesis of no difference in overall survival between
RECIST v1.1 progression, or informed consent with- the two groups was rejected, and key secondary efficacy
drawal. Tumour imaging was done at baseline and every endpoints could then be tested in the same order (ie,
9 weeks (every 12 weeks after week 54). Atezolizumab objective response rate followed by progression-free
treatment could continue beyond radiographic pro- survival). The primary efficacy analysis was planned when
4 www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X
Articles
roughly 152 deaths were observed in the IC2/3 population,
IC2/3 population ITT population
403 deaths were observed in the IC1/2/3 population, and
652 deaths were observed in the intention-to-treat Atezolizumab Chemotherapy Atezolizumab Chemotherapy
group (n=116) group (n=118) group (n=467) group (n=464)
population, whichever occurred last. There was no
planned maximum follow-up period or interim analysis (Continued from previous page)
based on the event-driven endpoints per protocol. The Previous cystectomy 57 (49%) 58 (49%) 199 (43%) 200 (43%)
number of events required to demonstrate overall survival Time since previous chemotherapy 35 (30%) 43 (36%) 160 (34%) 160 (34%)
<3 months
benefit with atezolizumab versus chemotherapy were
Number of previous systemic regimens in the metastatic setting
estimated on the basis of a two-sided significance level
0 43 (37%) 41 (35%) 131 (28%) 120 (26%)
of 5%, 94% power in the IC2/3 subgroup analysis
1 54 (47%) 59 (50%) 249 (53%) 261 (56%)
with an hazard ratio (HR) of 0·57 (corresponding to a
2 18 (16%) 18 (15%) 79 (17%) 74 (16%)
median overall survival improvement from 7·5 months
≥3 1 (1%) 0 8 (2%) 9 (2%)‡
to 13·2 months), 98% power in the IC1/2/3 analysis with
Previous systemic regimen setting
an HR of 0·68 (corresponding to a median overall
survival improvement from 7·5 months to 11 months), Metastatic 73 (63%) 77 (65%) 336 (72%) 344 (74%)
97% power for the intention-to-treat population with Neoadjuvant or adjuvant 37 (32%) 37 (31%) 117 (25%) 108 (23%)
chemotherapy with progression
an HR of 0·74 (corresponding to a median overall survival
within ≤12 months
improvement from 7·5 months to 10·1 months),
Other§ 6 (5%) 4 (3%) 14 (3%) 12 (3%)
a 1:1 randomisation ratio, and a dropout rate of 5% per
year over 24 months. Data are median (range), n (%), or n/N (%), unless otherwise specified. IC2/3=patients with programmed
death-ligand-1 expression on 5% or more of tumour-infiltrating immune cells. ITT=intention-to-treat. ECOG=Eastern
In analysis of overall survival, patients who were not
Cooperative Oncology Group. *Defined as liver, lung, bone, any non-lymph-node, or soft tissue metastasis. †Refers to
reported to have died by the data cutoff date were censored an ECOG performance status of 1 or more, presence of baseline liver metastases, and a haemoglobin concentration of
at the last date they were known to be alive (or at less than 10 g/dL. ‡One (<1%) patient in the chemotherapy group received four previous systemic regimens for
metastatic disease. §Refers to neoadjuvant or adjuvant chemotherapy with progression after 12 months, neoadjuvant
randomisation day for those with no post-baseline data).
or adjuvant chemotherapy with progression time unknown, and other treatment settings.
We used the Kaplan–Meier approach to estimate overall
survival, progression-free survival, and duration of Table 1: Baseline characteristics
response, with Brookmeyer–Crowley methodology used
to estimate 95% CIs. HRs were estimated with a stratified (n=467) or chemotherapy (n=464; figure 1). The treated
Cox regression analysis (stratification factors were the (safety-evaluable) population included 902 patients
same as those used for randomisation, unless otherwise (figure 1). Of 443 patients who received chemotherapy,
indicated). RECIST v1.1 objective response rates and 242 (55%) received vinflunine, 148 (33%) received
95% CIs for each treatment group were calculated with paclitaxel, and 53 (12%) received docetaxel (figure 1).
the Clopper–Pearson method and were compared Baseline characteristics between groups were similar in
between groups with the Mantel–Haenszel test. We used both the IC2/3 and intention-to-treat populations (table 1).
descriptive statistics to summarise study drug exposure At data cutoff (March 13, 2017) in the intention-to-
(treatment duration, number of doses, and dose intensity) treat population, 133 (28%) of 467 patients remained
for each treatment group. Safety-evaluable patients in the study in the atezolizumab group, and
included randomised patients who received any amount 89 (19%) of 464 patients remained in the study in the
of study treatment. Deaths were reported during the study chemotherapy group (figure 1). Treated patients received
or follow-up period and summarised by treatment group. atezolizumab for a median of 2·8 months (range 0–24),
We did statistical analysis with SAS (version 9.2). An vinflunine for a median of 2·1 months (0–15), paclitaxel
independent data monitoring committee reviewed safety for a median of 2·1 months (0–23), and docetaxel for a
roughly every 6 months. This study, which is ongoing median of 1·6 months (0–10). 81 (18%) patients who
but not recruiting participants, is registered with received atezolizumab, 12 (5%) who received vinflunine,
ClinicalTrials.gov, number NCT02302807. and two (1%) who received paclitaxel were treated for
1 year or more. At data cutoff, 65 (14%) patients receiving
Role of the funding source atezolizumab and nine (2%) patients receiving chemo-
The sponsor of the study had a role in study design, data therapy remained on treatment (figure 1). After treatment
collection, data analysis, and data interpretation. All discontinuation, 108 (23%) patients in the atezolizumab
authors had full access to all the data in the study, and the group and 118 (25%) patients in the chemotherapy group
corresponding author had final responsibility for the received at least one subsequent non-protocol treatment
decision to submit for publication. (appendix p 13), with 28 (6%) patients in the chemotherapy
group receiving post-protocol immunotherapy. The
Results median follow-up duration in the intention-to-treat
Between Jan 13, 2015, and Feb 15, 2016, we randomly population was 17·3 months (range 0–24·5). A total of
assigned 931 patients (intention-to-treat population) from 674 (72%) deaths occurred: 324 in the atezolizumab group
198 sites (appendix pp 9–12) to receive atezolizumab and 350 in the chemotherapy group.
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 5
Articles
analyses for overall survival were evaluated in subgroups
Overall survival
on the basis of baseline characteristics (appendix p 18).
Events/ Median overall 12 month overall
number survival survival rate Most efficacy differences between treatment groups were
of patients (months; 95% CI) (95% CI) marginal (appendix p 18). For patients receiving
100
chemotherapy, vinflunine outperformed study expec-
80 Stratified HR 0·87, 95% Cl 0·63–1·21; p=0·41 tations; unstratified HRs were 0·95 (95% CI 0·62–1·45)
and 0·69 (0·44–1·10) in subgroups based on chemo-
60 therapy stratification with vinflunine (n=106) and taxanes
(n=128), respectively. We also recorded variations in
40 overall survival HRs for upper-tract renal pelvis urothelial
tumours (appendix p 18).
20
Confirmed objective response rates were similar between
0 treatment groups in the IC2/3 population (table 2).
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1819 202122 2324 25 16 (62%) of 26 responders to atezolizumab and five (20%) of
Number at risk 25 responders to chemotherapy had ongoing responses;
Atezolizumab 11611210088 85 82 77 73 71 63 58 55 51 47 39 35 27 23 19 15 11 6 6 1
Chemotherapy 11810910095 91 85 82 75 71 65 61 51 47 41 32 28 24 18 15 11 9 7 5 2 1 the duration of response was numerically longer in
the atezolizumab group (table 2, figure 2). Progression-
free survival was numerically longer in patients given
100 Stratified HR 1·01 , 95% Cl 0·75–1·34
chemotherapy; however, patients given atezolizumab had
80 fewer progression-free survival events (table 2, figure 2).
The proportion of patients with adverse events
60 was similar between groups in the IC2/3 and intention-
to-treat populations, although results for the intention-to-
40
treat population were more robust in view of the higher
number of patients (table 3). In the IC2/3 population,
20
treatment-related adverse events leading to treatment
0 discontinuation occurred in seven (6%) of 114 patients in
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
the atezolizumab group and 17 (15%) of 112 patients in
Number at risk
Atezolizumab 11610881 53 50 42 38 33 33 30 29 26 24 19 19 19 12 12 8 5 5 1 1 1 the chemotherapy group (appendix p 14). We recorded
Chemotherapy 11810686 68 62 44 41 31 28 24 21 18 18 14 14 13 9 7 5 4 4 1
two (2%) atezolizumab-related deaths and two (2%)
chemotherapy-related deaths in the IC2/3 population.
These safety results were mirrored in the intention-to-
treat population, in which treatment discontinuations due
to adverse events occurred in 16 (3%) of 459 patients in the
atezolizumab group and 63 (14%) of 443 patients in the
chemotherapy group; treatment-related deaths occurred
in four (1%) and nine (2%) patients, respectively
(appendix pp 14, 15). Adverse events of any grade deemed
treatment related by the investigator occurred in 85 (75%)
atezolizumab-treated patients versus 99 (88%) chemo-
therapy-treated patients in the IC2/3 population (table 3).
For both the IC2/3 and intention-to-treat populations,
treatment-related adverse events occurring in 10% or
more of patients in both groups were fatigue, asthenia,
decreased appetite, and diarrhoea (table 3). For both
populations, treatment-related fatigue, nausea, con-
stipation, and alopecia of any grade occurred in 22% or
more of patients receiving chemotherapy, but did not
meet this threshold for patients receiving atezolizumab
The efficacy analysis was first done in the IC2/3 (table 3). Conversely, treatment-related pruritus was more
population. Overall survival did not differ significantly common in the atezolizumab group of the IC2/3 and the
between the atezolizumab group and the chemotherapy intention-to-treat populations (table 3). In the IC2/3
group (median 11·1 months [95% CI 8·6–15·5] vs population, treatment-related rash was likewise more
10·6 months [8·4–12·2]; stratified HR 0·87, 95% CI common with atezolizumab then chemotherapy (table 3).
0·63–1·21; p=0·41; figure 2), precluding further formal In both the IC2/3 and intention-to-treat populations,
statistical comparisons and rendering subsequent grade 3 or 4 treatment-related adverse events were less
analyses exploratory in nature. Exploratory forest plot common with atezolizumab than chemotherapy (table 3).
6 www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X
)%(
lavivrus
llarevO
Atezolizumab
Chemotherapy
)%(
lavivrus
eerf-noissergorP
Progression-free survival
100
80
60
40
20
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Number at risk
Atezolizumab 26 26 25 24 23 20 20 17 17 16 15 10 8 8 5 5 3 1 1 1 1 1
Chemotherapy 25 25 25 25 25 21 17 14 13 10 10 9 9 8 4 4 3 3 3 1
)%(
esnopser
evitcejbO
72/116 11·1 (8·6–15·5) 46·4% (37·3–55·6)
88/118 10·6 (8·4–12·2) 41·2% (32·2–50·3)
·· ··
··
··
·· ·· ··
Duration of response*
Time (months)
··
·· ·· ··
Figure 2: Efficacy outcomes in patients with programmed death-ligand-1 expression on 5% or more of
tumour-infiltrating immune cells (IC2/3 population)
Complete data for progression-free survival and duration of response are shown in table 2. Vertical lines indicate
censored events (death or progression). HR=hazard ratio. *In the subset of patients with objective response.
Articles
Subsequent overall survival analyses were done in the
IC2/3 population ITT population
intention-to-treat population for exploratory purposes
Atezolizumab Chemotherapy Atezolizumab Chemotherapy
only (figure 3, appendix p 19). We did this analysis for
group (n=116) group (n=118) group (n=467) group (n=464)
two primary reasons: to explore potential reasons for
Progression-free survival
the negative primary endpoint in the IC2/3 population
and to inform understanding around the hypothesis Patients with event (%)* 93 (80%) 105 (89%) 407 (87%) 410 (88%)
that atezolizumab would provide benefit regardless of Median (months; 95% CI) 2·4 (2·1–4·2) 4·2 (3·7–5·0) 2·1 (2·1–2·2) 4·0 (3·4–4·2)
PD-L1 expression, but would perform better in the Objective response†
IC2/3 subgroup. Overall survival in the intention-to- Number of evaluable 113 116 462 461
patients
treat population was numerically improved in the
Number of patients with 26 (23·0%, 25 (21·6%, 62 (13·4%, 62 (13·4%,
atezolizumab group compared with the chemotherapy
response (%, 95% CI) 15·6–31·9) 14·5–30·2) 10·5–16·9) 10·5–16·9)
group (figure 3). At 12 months, the overall survival rate
Best overall response†
was 39·2% (95% CI 34·8–43·7) with atezolizumab and
Complete response 8 (7%) 8 (7%) 16 (3%) 16 (3%)
32·4% (28·0–36·8) with chemotherapy (figure 3).
Partial response 18 (16%) 17 (15%) 46 (10%) 46 (10%)
Results from prespecified subgroup analyses of overall
Stable disease 23 (20%) 37 (32%) 92 (20%) 162 (35%)
survival in the intention-to-treat population by baseline
Progressive disease 47 (42%) 30 (26%) 240 (52%) 150 (32%)
and clinical characteristics generally agreed with those
Missing or unevaluable 17 (15%) 24 (21%) 68 (15%) 87 (19%)
from the IC2/3 population (figure 3). In exploratory
Duration of response†
analyses we additionally assessed overall survival in the
Patients with event (%)* 10/26 (38%) 20/25 (80%) 23/62 (37%) 49/62 (79%)
intention-to-treat population by investigator-prespecified
Median (months; 95% CI) 15·9 (10·4–NE) 8·3 (5·6–13·2) 21·7 (13·0–21·7) 7·4 (6·1–10·3)
chemotherapy subgroup (taxane and vinflunine).
Atezolizumab demonstrated better comparative overall Data are n (%) or n/N (%), unless otherwise specified. IC2/3=patients with programmed death-ligand-1 expression
survival in patients intended for treatment with taxanes on 5% or more of tumour-infiltrating immune cells. ITT=intention-to-treat. NE=not estimable. *Progressive disease or
death. †Confirmed investigator-assessed objective responses.
(median 8·3 months [95% CI 6·6–9·8; n=215]
vs 7·5 months [6·7–8·6; n=214]; HR 0·73, 95% CI Table 2: Secondary and exploratory efficacy outcomes
0·58–0·92), but not in those given vinflunine (median
9·2 months [7·9–10·4; n=252] vs 8·3 months [6·9–9·6;
n=250]; 0·97, 0·78–1·19; appendix p 21). observed between PD-L1 expression and tumour
Confirmed objective response rates were lower for mutation burden was modest (r=0·13). We assessed
both atezolizumab-treated and chemotherapy-treated overall survival based on patients whose samples had
patients in the intention-to-treat population than for high (at or above the median) or low (below the median)
those in the IC2/3 population (table 2). Median response values for tumour mutation burden (appendix p 23). For
durations were longer with atezolizumab than patients with samples with high tumour mutation
chemotherapy in the intention-to-treat population burden (n=274), overall survival was numerically longer
(table 2, figure 3), mirroring the results in the IC2/3 for those treated with atezolizumab than for those
population (table 2, figure 2). In the intention-to-treat treated with chemotherapy (median 11·3 months
population, 39 (63%) of 62 responders receiving [95% CI 8·7–13·2] vs 8·3 months [7·2–10·4]; HR 0·68,
atezolizumab had ongoing responses compared with 95% CI 0·51–0·90), whereas for those with samples
13 (21%) of 62 responders receiving chemotherapy. with low tumour mutation burden (n=270), survival was
Progression-free survival in this population was similar between groups (median 8·3 months [6·4–9·8]
longer in patients given chemotherapy than in those vs 8·1 months [6·2–10·4]; 1·00, 0·75–1·32; appendix
given atezolizumab (table 2, figure 2). The appendix p 23). We next evaluated whether PD-L1 status conferred
(pp 16, 20, 22) shows results for additional exploratory a survival advantage for patients with samples with high
analyses of key efficacy endpoints (overall survival, tumour mutation burden (appendix p 23). In patients
objective response rate and duration, and progression- with samples with high tumour mutation burden and
free survival) for the IC1/2/3 population. PD-L1 IC2/3 samples (n=96), median survival for
In an exploratory biomarker analysis, 544 (58%) of patients given atezolizumab was 17·8 months (95% CI
931 patients in the intention-to-treat population 9·7–not estimable) versus 10·6 months (8·2–14·3) for
had tumour samples evaluable for measurement of those given chemotherapy (HR 0·50, 95% CI 0·29–0·86;
tumour mutation burden. Baseline characteristics of appendix p 23).
the overall biomarker-evaluable population, including In a further analysis, we evaluated prespecified
PD-L1 status (appendix p 23), were generally balanced patient-reported outcomes based on EORTC QLQ-C30
between treatment groups and representative of the global health status, physical functioning, and fatigue
intention-to-treat population. Median tumour mutation scores (appendix pp 24, 25), and measured baseline
burden in the biomarker-evaluable population was scores in the intention-to-treat population (appendix p 17).
9·65 mutations per megabase (IQR 8·78) and was also Mean changes in these scores initially deteriorated,
similar between groups (appendix p 23). The correlation but returned to baseline after several cycles and re-
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 7
Articles
prolonged with atezolizumab for physical function and
IC2/3 population ITT population
fatigue (appendix p 24).
Atezolizumab Chemotherapy Atezolizumab Chemotherapy
group (n=114) group (n=112) group (n=459) group (n=443) Discussion
Most common treatment-related adverse events of any grade* In this randomised phase 3 study, the primary endpoint
All 85 (75%) 99 (88%) 319 (69%) 395 (89%) of overall survival improvement with atezolizumab was
Fatigue 18 (16%) 27 (24%) 71 (15%) 116 (26%) not met in patients with metastatic urothelial carcinoma
Pruritus 14 (12%) 3 (3%) 55 (12%) 14 (3%) with at least 5% PD-L1 expression on tumour-infiltrating
Asthenia 14 (12%) 23 (21%) 51 (11%) 79 (18%) immune cells, precluding additional formal statistical
Rash 13 (11%) 7 (6%) 40 (9%) 21 (5%) analysis. Our hierarchical study design hypothesised
Pyrexia 12 (11%) 4 (4%) 40 (9%) 25 (6%) that efficacy would be associated with PD-L1 expression
Decreased appetite 11 (10%) 20 (18%) 56 (12%) 81 (18%) on the basis of phase 1 and 2 findings with
Diarrhoea 11 (10%) 15 (13%) 50 (11%) 66 (15%) atezolizumab12,16,19 and other checkpoint inhibitors.20,21
Nausea 9 (8%) 25 (22%) 46 (10%) 117 (26%) Unexpectedly, in our study, overexpression of PD-L1
Dyspnoea 9 (8%) 3 (3%) 18 (4%) 19 (4%) (SP142 immunohistochemistry assay) resulted in a
Anaemia 8 (7%) 18 (16%) 25 (5%) 84 (19%) more favourable outcome (longer overall survival and
Constipation 5 (4%) 44 (39%) 29 (6%) 145 (33%) increased response rates) with both chemotherapy and
Vomiting 5 (4%) 17 (15%) 16 (3%) 62 (14%) atezolizumab, negating its potentially predictive effects.
Abdominal pain 5 (4%) 8 (7%) 9 (2%) 34 (8%) The reasons for these results remain unclear and differ
Arthralgia 4 (4%) 13 (12%) 17 (4%) 40 (9%) from previous positive phase 3 studies of atezolizumab
Myalgia 4 (4%) 9 (8%) 13 (3%) 48 (11%) in patients with advanced non-small-cell lung cancer14
Neutropenia 3 (3%) 13 (12%) 3 (1%) 64 (14%) and pembrolizumab in patients with metastatic
urothelial carcinoma (KEYNOTE-045).9 An exp lanation
Mucosal inflammation 3 (3%) 9 (8%) 15 (3%) 44 (10%)
for these inverse results is not readily available,
Peripheral neuropathy 2 (2%) 15 (13%) 3 (1%) 50 (11%)
although PD-L1 assay disparities—widespread in this
Dysgeusia 2 (2%) 7 (6%) 6 (1%) 22 (5%)
field22—might contribute to these differences. Indeed,
Paraesthesia 1 (1%) 6 (5%) 7 (2%) 25 (6%)
the assay used in KEYNOTE-045 (22C3 antibody)
Decreased weight 1 (1%) 5 (4%) 12 (3%) 26 (6%)
measured PD-L1 expression on both immune and
Alopecia 0 33 (29%) 0 120 (27%)
tumour cells, which, unlike SP142, was associated with
Peripheral sensory neuropathy 0 11 (10%) 3 (1%) 39 (9%)
a poor prognosis.9 These results underscore the risks of
Stomatitis 0 9 (8%) 10 (2%) 33 (7%)
biomarker-focused statistical designs without supportive
Decreased neutrophil count 0 8 (7%) 0 28 (6%)
randomised data, and highlight the need for improved
Febrile neutropenia 0 5 (4%) 1 (<1%) 25 (6%)
predictive biomarkers for cancer immunotherapy.23,24
Grade 3 or 4 treatment-related adverse events†
Kaplan–Meier analysis also revealed non-proportional
Fatigue 4 (4%) 2 (2%) 7 (2%) 18 (4%)
hazards, with curve separation and inflection occurring
Anaemia 3 (3%) 3 (3%) 9 (2%) 21 (5%)
relatively late. This outcome is common with immune
Neutropaenia 2 (2%) 9 (8%) 2 (<1%) 49 (11%)
checkpoint inhibitors,9,25 but appears more pronounced
Peripheral neuropathy 1 (1%) 3 (3%) 1 (<1%%) 8 (2%)
here, partially accounting for the statistical findings of
Asthenia 1 (1%) 2 (2%) 8 (2%) 18 (4%)
the study. Atezolizumab was associated with a longer
Neutrophil count decreased 0 7 (6%) 0 26 (6%)
duration of response, consistent with other immune
Febrile neutropenia 0 5 (4%) 1 (<1%) 25 (6%) checkpoint inhibitors in metastatic urothelial carcinoma
Constipation 0 4 (4%) 0 20 (5%) and associated with notable 12 month landmark
Peripheral sensory neuropathy 0 3 (3%) 0 6 (1%) overall survival rates.
Ileus 0 3 (3%) 0 4 (1%) The adverse event profile for atezolizumab was
White blood cell count decreased 0 2 (2%) 0 11 (2%) favourable compared with chemotherapy for both
the IC2/3 and intention-to-treat populations. Patients
Data are n (%). IC2/3=patients with programmed death-ligand-1 expression on 5% or more of tumour-infiltrating
immune cells. ITT=intention-to-treat. *Adverse events of all grades reported in at least 5% of patients in either group. receiving atezolizumab had lower rates of adverse
†Adverse events reported in at least 2% of patients in either group. events leading to treatment discontinuation and fewer
treatment-related adverse events than did those receiving
Table 3: Treatment-related adverse events
chemotherapy. The safety profiles for cancer immuno-
therapies and chemotherapy are distinct; rates for
mained stable thereafter for the atezolizumab group; grade 3 or 4 adverse events of special interest were less
mean scores changes were worse, particularly for than 10% for atezolizumab in IC2/3 and intention-to-
fatigue, in the chemotherapy group (appendix p 25). treat patients, with immune-mediated events generally
Although event-to-patient deterioration rates remained consistent with previous atezolizumab studies.16 These
low at time of analysis, median time to deterioration was data further translated to sustained health-related quality
similar between groups for global health status, and of life with atezolizumab.
8 www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X
Articles
Because of an absence of global consensus, the control
Overall survival
group permitted different chemotherapy regimens;
100
however, our results revealed numerical differences
when efficacy was evaluated by chemotherapy type.
80
Survival with vinflunine was better than the protocol 324/467 8·6 (7·8–9·6) 39·2 % (34·8–43·7)
350/464 8·0 (7·2–8·6) 32·4 % (28·0–36·8)
hypothesised on the basis of previous studies,6,9 60
potentially compromising the statistical assumptions.
This finding was not exclusive to the PD-L1-selected 40
subgroups, but was also noted in the intention-to-treat
population. Although previous data suggested similar 20
overall survival rates for vinflunine, paclitaxel, and
docetaxel,6,7 comparative randomised studies with these 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
drugs have not been done, which calls into question the Number at risk
suitability of a mixed control group and potentially affects Atezolizumab 467443405348327309280259245218201192177166138113 90 76 59 47 34 20 13 5 1
Chemotherapy 46442839736433029926824421919117515614012699 78 60 49 42 30 17 11 7 2 1
our results. Furthermore, improved clinical proficiency
and post-approval patient selection in western Europe,26–29 Duration of response*
where most patients were enrolled, might have also
contributed to these findings. The primary analysis of
KEYNOTE-045 did not pursue a hierarchical PD-L1
biomarker-driven approach and demonstrated positive
survival results for pembrolizumab versus chemotherapy;
however, comparisons between biomarker-selected and
unselected trials are challenging because of intrinsic
differences in patient populations.
We did prespecified exploratory efficacy analyses of the
intention-to-treat population to better understand the
results of the study and evaluate atezolizumab versus 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
chemotherapy in a biomarker-unselected comparison, Time (months)
which, with more than 900 patients treated in that 62 62 61 58 56 50 50 45 42 38 35 25 23 22 14 14 9 5 5 3 2 2
62 62 62 61 59 48 40 30 28 23 23 17 16 15 8 7 5 5 4 2 ·· ··
population, is to our knowledge the largest interventional
study of metastatic urothelial carcinoma. Median
survival rates were shorter in the intention-to-treat
population than in the IC2/3 population, potentially due
to the enrichment of responders occurring in both with metastatic urothelial carcinoma previously treated
groups in the IC2/3 cohort. Comparative efficacy signals with platinum-containing regimens. Atezolizumab is
(overall survival HR 0·85, 95% CI 0·73–0·99) were approved in this setting in the US.30 EU approval
similar to those in the IC2/3 population, underlining the of atezolizumab was granted in patients with
problem with our biomarker enrichment hypothesis for platinum-treated metastatic urothelial carcinoma partly
the primary endpoint. Toxicity and duration of response on the basis of these data.31
for the IC2/3 and intention-to-treat populations were We attempted to identify alternative biomarkers for
similar. Exploratory analysis showed that notable 1 year atezolizumab in view of the absence of predictive values
milestone survival rates were achieved with atezolizumab for the PD-L1 immunohistochemistry biomarker. Tumour
compared with chemotherapy in the intention-to- mu tation burden, which is high in bladder cancer, is
treat population (39·2% vs 32·4%). Similar to the thought to be a surrogate marker for neoantigen
IC2/3 subgroup, delayed separation of the Kaplan–Meier expression and might be required for immune recognition
curves was observed when indirectly compared with of tumours. Previous exploratory studies have shown that
KEYNOTE-045. Median progression-free survival is tumour mutation burden outperforms PD-L1 expression
short for all immune checkpoint inhibitors in this as a biomarker for nivolumab in other tumour types.32
setting, irrespective of biomarker selection. Different Our study showed similar results. These consistent
strategies will be required to achieve disease control in results across different tumour types suggest similar
most patients. These data from the intention-to-treat broad mechanisms of action for this group of drugs.
population were not formally tested for statistical These results are hypothesis generating; if validated
significance. However, in view of the high unmet need in future trials, tumour mutation burden—alone or
in this population, the well tolerated, durable remissions with other biomarkers—could improve the accuracy of
observed with atezolizumab, and the complications selection of patients for monotherapy.
associated with chemotherapy, the benefit–risk ratio for
Contributors
atezolizumab can be considered favourable for patients TP, NC, XS, and CLD contributed to the design of the study.
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 9
)%(
esnopser
evitcejbO
Atezolizumab
Chemotherapy
0
0
)%(
lavivrus
llarevO
Events/ Median overall 12 month overall
number survival survival rate
of patients (months; 95% CI) (95% CI)
Stratified HR 0·85, 95% Cl 0·73–0·99
··
··
100
80
60
40
20
0
0
Number at risk
Atezolizumab ··
Chemotherapy ··
Figure 3: Exploratory efficacy outcomes in the intention-to-treat population
HR=hazard ratio. *In the subset of patients with objective response.
Articles
All authors contributed to data collection, data analysis, and data J Clin Oncol 2009; 27: 4454–61.
interpretation. All authors contributed to writing of the manuscript, 7 Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized
approved the final version, and agree to be accountable for all aspects trial of docetaxel plus vandetanib versus docetaxel plus placebo in
of the report. platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012;
30: 507–12.
Declaration of interests
8 Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M,
TP has received research funding from Roche and AstraZeneca, Zang X. The expanding repertoire of targets for immune
and honoraria from Roche, Bristol-Myers Squibb, and Merck. ID has checkpoint inhibition in bladder cancer: what lies beneath the tip of
received honoraria for consulting or advisory roles from Jansen, Roche, the iceberg, PD-L1. Urol Oncol 2017; published online May 8.
Amgen, and Novartis, and travel support and accommodation expenses DOI:10.1016/j.urolonc.2017.04.007.
from Astellas. MSvdH has received a research grant from Astellas, 9 Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as
reimbursement for patient care and data management of study second-line therapy for advanced urothelial carcinoma.
participants from Roche–Genentech, and honoraria for advisory roles N Engl J Med 2017; 376: 1015–26.
from Roche–Genentech, Astellas, and AstraZeneca. YL has received 10 Chen DS, Mellman I. Oncology meets immunology:
honoraria from Roche, Sanofi, Astellas, Janssen, iPSEN, and the cancer-immunity cycle. Immunity 2013; 39: 1–10.
Bristol-Myers Squibb, and a research grant from Sanofi. SO has 11 Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of
received honoraria from Roche, Novartis, iPSEN, Bristol-Myers Squibb, response to the anti-PD-L1 antibody MPDL3280A in cancer
and Bayer. AB has received honoraria from Roche, Novartis, Pfizer, patients. Nature 2014; 515: 563–67.
Bristol-Myers Squibb, and AstraZeneca; research grants and 12 Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1)
non-financial support from Novartis and Pfizer; and investigator and treatment leads to clinical activity in metastatic bladder cancer.
institutional support from Roche. AF has received honoraria from Nature 2014; 515: 558–62.
Janssen, Pfizer, Roche, AstraZeneca, MSD, and Pierre Fabre, and travel 13 McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab,
support and accommodation expenses from Janssen, Pfizer, MSD, an anti-programmed death-ligand 1 antibody, in metastatic renal
Roche, AstraZeneca, and Pierre Fabre. SH has served in advisory roles cell carcinoma: long-term safety, clinical activity, and immune
correlates from a phase Ia study. J Clin Oncol 2016; 34: 833–42.
for Roche, Merck, AstraZeneca, Pierre Fabre, Bayer, Janssen, and
Bristol-Myers Squib, and has received educational grants and 14 Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus
docetaxel in patients with previously treated non-small-cell lung
institutional funding from Cancer Research UK, Boehringer Ingelheim,
cancer (OAK): a phase 3, open-label, multicentre randomised
Janssen, and Eli Lilly. TT has received honoraria from Daiichi-Sankyo.
controlled trial. Lancet 2017; 389: 255–65.
NL, EEK, RB, PSH, SM, NC, XS, CLD, and MCG are employees of
15 Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line
Genentech and own Roche stock. AR has received honoraria, travel
treatment in cisplatin-ineligible patients with locally advanced and
support, and accommodation expenses from Pfizer, Novartis, metastatic urothelial carcinoma: a single-arm, multicentre,
Bristol-Myers Squib, AstraZeneca, Roche, MSD, and iPSEN and a phase 2 trial. Lancet 2017; 389: 67–76.
research grant from Pfizer. NJV, UDG, MMR, DC, and GG declare no 16 Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in
competing interests. patients with locally advanced and metastatic urothelial carcinoma
Acknowledgments who have progressed following treatment with platinum-based
chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;
This study was funded by F Hoffmann-La Roche–Genentech. We
387: 1909–20.
thank the patients participating in this trial and the clinical study site
17 Frampton GM, Fichtenholtz A, Otto GA, et al. Development and
investigators (appendix pp 9–12). We also thank Gregg Fine,
validation of a clinical cancer genomic profiling test based on
Daniel Chen, and Cathi Ahearn for their contributions to study design;
massively parallel DNA sequencing. Nat Biotechnol 2013;
Mika Derynck, Daniel Chen, and Cathi Ahearn for their input in data 31: 1023–31.
interpretation; Elisabeth Piault-Louis and Caroleen Quach for their
18 Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of
involvement with patient-reported outcomes assessments, 100,000 human cancer genomes reveals the landscape of tumor
Zachary Boyd for his contribution to biomarker analyses; and mutational burden. Genome Med 2017; 9: 34.
Flavia DiNucci and Xiaohui Wen for their contributions to safety 19 Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus
analyses. Medical writing assistance was provided by Ashley J Pratt docetaxel for patients with previously treated non-small-cell lung
(Health Interactions, San Francisco, CA, USA) and was funded by cancer (POPLAR): a multicentre, open-label, phase 2 randomised
F Hoffmann-La Roche. controlled trial. Lancet 2016; 387: 1837–46.
20 Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of
References
durvalumab (MEDI4736), an anti-programmed cell death ligand-1
1 National Cancer Institute Surveillance, Epidemiology, and End
immune checkpoint inhibitor, in patients with advanced urothelial
Results Program. Cancer stat facts: bladder cancer. http://seer.
bladder cancer. J Clin Oncol 2016; 34: 3119–25.
cancer.gov/statfacts/html/urinb.html (accessed April 28, 2017).
21 Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of
2 Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized
pembrolizumab in patients with locally advanced or metastatic
comparison of cisplatin alone or in combination with methotrexate,
urothelial cancer (KEYNOTE-012): a non-randomised, open-label,
vinblastine, and doxorubicin in patients with metastatic urothelial
phase 1b study. Lancet Oncol 2017; 18: 212–20.
carcinoma: a cooperative group study. J Clin Oncol 1992;
10: 1066–73. 22 Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1
expression on tumor-infiltrating mononuclear cells and overall
3 von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival
survival in patients with urothelial carcinoma. Ann Oncol 2015;
results of a randomized trial comparing gemcitabine plus cisplatin,
26: 812–17.
with methotrexate, vinblastine, doxorubicin, plus cisplatin in
patients with bladder cancer. J Clin Oncol 2005; 23: 4602–08. 23 Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint
inhibition in metastatic urothelial cancer. Eur Urol 2017; 72: 477–81.
4 Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer: ESMO practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 24 Chen DS, Mellman I. Elements of cancer immunity and the
25 (suppl 3): iii40–48. cancer-immune set point. Nature 2017; 541: 321–30.
5 National Comprehensive Cancer Network. NCCN clinical practice 25 Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
guidelines in oncology: bladder cancer. V5.2017. https://www.nccn. everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;
org/professionals/physician_gls/pdf/bladder.pdf 373: 1803–13.
(accessed Sep 7, 2017). 26 Castellano D, Puente J, de Velasco G, et al. Safety and effectiveness
6 Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of of vinflunine in patients with metastatic transitional cell carcinoma
vinflunine plus best supportive care compared with best supportive of the urothelial tract after failure of one platinum-based systemic
care alone after a platinum-containing regimen in patients with therapy in clinical practice. BMC Cancer 2014; 14: 779.
advanced transitional cell carcinoma of the urothelial tract. 27 Garcia-Donas J, Font A, Perez-Valderrama B, et al.
10 www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X
Articles
Maintenance therapy with vinflunine plus best supportive care 29 Pistamaltzian N, Tzannis K, Pissanidou V, et al. Treatment of
versus best supportive care alone in patients with advanced relapsed urothelial bladder cancer with vinflunine: Real-world
urothelial carcinoma with a response after first-line chemotherapy evidence by the hellenic genitourinary cancer group.
(MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, Anticancer Drugs 2016; 27: 48–53.
open-label, phase 2 trial. Lancet Oncol 2017; 18: 672–81. 30 Tecentriq (atezolizumab): package insert. South San Francisco, CA:
28 Medioni J, Di Palma M, Guillot A, Spaeth D, Theodore C. Genentech, 2017.
Efficacy and safety of vinflunine for advanced or metastatic 31 Tecentriq (atezolizumab): summary of product characteristics.
urothelial carcinoma in routine practice based on the french Welwyn Garden City, UK: Roche Registration Limited, 2017.
multi-centre CURVE study. BMC Cancer 2016; 16: 217. 32 Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in
stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;
376: 2415–26.
www.thelancet.com Published online December 18, 2017 http://dx.doi.org/10.1016/S0140-6736(17)33297-X 11
